Tue, 02nd Feb 2016 09:21
** Hikma rises 3 pct after BAML upgrades to "buy"from "neutral"
** Says it sees generous synergies from Roxane Laboratoriesacquisition; expects co to shut either its own or Roxane's USgenerics manufacturing plant
** Adds minimal colour on current pipeline but some largeopportunities expected - sees $725-775m revenues in FY17
** Top riser on FTSE 100
(RM: alasdair.pal.thomsonreuters.com@reuters.net)
(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:
(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth readi...
(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reported an encouraging start to the year supported by all three business segments.
(Sharecast News) - Pharmaceuticals group Hikma said it has made a "strong and encouraging start" to 2024, with all three business segments performing ...
Hikma Pharmaceuticals (HIK)